HMN-154 |
| カタログ番号GC33321 |
HMN-154 は新規のベンゼンスルホンアミド抗がん化合物です。 KB および Colon38 細胞をそれぞれ 0.0026 および 0.003 μg/mL の IC50 値で阻害します。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 173528-92-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
HMN-154 is a novel benzenesulfonamide anticancer compound; inhibits KB and colon38 cells with IC50 values of 0.0026 and 0.003 μg/mL, respectively.
HMN-154 interacts with NF-YB and thereby interrupts the binding of the NF-Y heterotrimer to DNA. NF-YB and thymosin β-10 are specific cellular binding proteins of HMN-154 and that this shared region is necessary for the binding to HMN-154. HMN-154 inhibits DNA binding of NF-Y to the human major histocompatibility complex class II human leukocyte antigen DRA Y-box sequence in a dose-dependent manner. HMN-154 shows very strong cytotoxicity against KB and colon38 cells with an IC50 value of 0.0026 and 0.003 μg/mL, respectively. HMN-154/BSA binds recombinant NF-YB or thymosin β-10 and the binding is inhibited by the addition of HMN-154 as the competitor. The binding between HMN-154 and NF-YB is specific and depends on its cytotoxicity[1].
[1]. Tanaka H, et al. Isolation of cDNAs encoding cellular drug-binding proteins using a novel expression cloning procedure: drug-western. Mol Pharmacol. 1999 Feb;55(2):356-63.
Average Rating: 5 (Based on Reviews and 5 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *